{arrow_up} Back to top

Risk Minimisation Materials

Search by company, common medicine name, or title of Risk Minimisation Material

Lucentis

Novartis Pharmaceuticals UK Ltd

{pdf_link}

Lucentis (ranibizumab) - Patient information booklet (AMD) - for patients

A booklet containing important safety information for patients treated with Lucentis (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD). An audio version is available on eMC.

{pdf_link}

Lucentis (ranibizumab) - Patient information booklet (CNV) - for patients

A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV)secondary to pathological myopia. An audio version is available on eMC.

{pdf_link}

Lucentis (ranibizumab) - Patient information booklet (DMO/PDR) - for patients

A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO). An audio version is available on eMC.

{pdf_link}

Lucentis (ranibizumab) - Patient information booklet (RVO) - for patients

A booklet containing important safety information for patients treated with Lucentis (ranibizumab) with visual impairment due to retinal vein occlusion (RVO). An audio version is available on eMC.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?